Advances in Diagnosis and Treatment of Transplant-Associated Thrombotic Microangiopathy --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.044
- Author:
Yu-Ke GENG
1
;
Tao WANG
1
;
Zhi-Qiang SONG
1
;
Jian-Min YANG
2
Author Information
1. Department of Hematology, Changhai Hospital Affiliated to Naval Military Medical University, Shanghai 200433, China.
2. Department of Hematology, Changhai Hospital Affiliated to Naval Military Medical University, Shanghai 200433, China . E-mail: chyangjianmin@163.com.
- Publication Type:Journal Article
- Keywords:
thrombotic microangiopathy;
treatment;
complication;
diagnosis;
hematopoietic stem cell transplantation
- MeSH:
Humans;
Thrombotic Microangiopathies/therapy*;
Prognosis;
Thrombosis/etiology*;
Risk Factors;
Hematopoietic Stem Cell Transplantation/adverse effects*
- From:
Journal of Experimental Hematology
2023;31(2):602-606
- CountryChina
- Language:Chinese
-
Abstract:
Transplantation-associated thrombotic microangiopathy (TA-TMA) is one of the serious complications mostly occurring within 100 days after hematopoietic stem cell transplantation (HSCT). Risk factors of TA-TMA include genetic predispositions, GVHD, and infections. The pathophysiological mechanisms of TA-TMA start with endothelial injury caused by complement activation, which leads to microvascular thrombosis, and microvascular hemolysis, ultimately resulting in multi-organ dysfunction. In recent years, the development of complement inhibitors has markedly improved the prognosis of TA-TMA patients. This review will give an update on risk factors, clinical manifestations, diagnosis, and treatment of TA-TMA, so as to provide references for clinical practice.
